A Phase 1 interventional study of [^14C]-alisertib and alisertib in Advanced Solid Tumors and Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-31.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Lymphoma by Takeda — 1 open to participants now, 2 under way, none of them phase 3. Lymphoma · Takeda.
Among the 26 studies in Lymphoma by Takeda, this one is the 23rd largest by enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2013, is one of 12 in phase 1, and was the 9th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →1 of the 26 studies in Lymphoma by Takeda is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in India
Ages 18+
By country, each count listing its studies:
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 6 · Phase 3 2 · Phase 4 3
First in 1997; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 36 across the 23 interventional studies, 1,000 across the 3 observational. Of the 24 that completed or were terminated, 17 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Lymphoma by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the mass balance (i.e. cumulative excretion of total radioactivity [TRA] in urine and feces) of alisertib and pharmacokinetic (PK) of alisertib in plasma and urine, and of TRA in plasma and whole blood.
The drug being tested in this study is called alisertib (MLN8237). Alisertib is being tested to treat participants who have advanced solid tumors or lymphomas. This study looked at mass balance, pharmacokinetics (PK), metabolism, elimination and safety of alisertib.
The study enrolled 3 patients. The study consisted of 2 parts: Part A and Part B. Participants received:
Participants were asked to take a single dose of [\^14C]-alisertib oral solution containing 80-100 μCi of total radioactivity (1.19-1.48 mCi/mmol) in Part A and alisertib 50 mg, orally, twice daily for 7 days in 21-day cycles until disease progression or unacceptable toxicity in Part B.
This single center trial was conducted in United States. The overall time to participate in this study was up to 117 days. Participants remained confined to clinic in Part A and made multiple visits to the clinic in Part B. Participants were contacted 30 days after last dose of alisertib in Part A (if not continuing in Part B), or were contacted by telephone or a final visit 30 days after receiving their last dose of alisertib in Part B for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Each participants must meet all of the following inclusion criteria to be enrolled in the study:
Exclusion Criteria:
Participants meeting any of the following exclusion criteria are not to be enrolled in the study:
Please note that there are additional exclusion criteria. The study center will determine if you meet all of the criteria.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: \[\^14C\]-alisertib 35 mg, oral solution containing 80 - 100 microcuries (μCi) of total radioactivity (1.19 - 1.48 mCi/mmol), orally, single dose on Day 1. Part B: Alisertib 50 mg, enteric coated tablets, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 3 Cycles).
Drug: [^14C]-alisertib · Drug: alisertib
\[\^14C\]-alisertib oral solution
Also known as: MLN8237
Alisertib enteric coated tablets
Also known as: MLN8237
Cmax: Maximum Observed Plasma Concentration for Alisertib and Drug-Related Material Following a Single Dose of [^14C]-Alisertib Oral Solution
Time frame: Predose and multiple timepoints post-dose (up to 240 hours)
Tmax: Time of First Occurrence of Cmax for Alisertib and Drug-Related Material in Plasma Following a Single Dose of [^14C]-Alisertib Oral Solution
Time frame: Predose and multiple timepoints post-dose (up to 240 hours)
AUClast: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Plasma Concentration for Alisertib and Drug-Related Material Following a Single Dose of [^14C]-Alisertib Oral Solution
Time frame: Predose and multiple timepoints post-dose (up to 240 hours)
AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Plasma Concentration for Alisertib and Drug-Related Material Following a Single Dose of [^14C]-Alisertib Oral Solution
Time frame: Predose and multiple timepoints post-dose (up to 240 hours)
T1/2: Terminal Half Life for Alisertib and Drug-Related Material in Plasma Following a Single Dose of [^14C]-Alisertib Oral Solution
Time frame: Predose and multiple timepoints post-dose (up to 240 hours)
CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Plasma Concentration for Alisertib Following a Single Dose of [^14C]-Alisertib Oral Solution
Time frame: Predose and multiple timepoints post-dose (up to 240 hours)
Ratio of Whole Blood Total Radioactivity (TRA) Cmax to Plasma TRA Cmax
Time frame: Predose and multiple timepoints post-dose (up to 240 hours)
Ratio of Alisertib Plasma Cmax to Drug-Related Material TRA Plasma Cmax
Time frame: Predose and multiple timepoints post-dose (up to 240 hours)
Ratio of Whole Blood TRA AUClast to Plasma TRA AUClast
Time frame: Predose and multiple timepoints post-dose (up to 240 hours)
Ratio of Alisertib Plasma AUClast to Drug-Related Material TRA Plasma AUClast
Time frame: Predose and multiple timepoints post-dose (up to 240 hours)
Ratio of Whole Blood TRA AUC∞ to Plasma TRA AUC∞
Time frame: Predose and multiple timepoints post-dose (up to 240 hours)
Ratio of Alisertib Plasma AUC∞ to Drug-Related Material TRA Plasma AUC∞
Time frame: Predose and multiple timepoints post-dose (up to 240 hours)
Fe: Fraction of Administered Dose of [^14C]-Alisertib Excreted in Urine
Time frame: Predose and multiple timepoints post-dose (up to 240 hours)
Fe: Fraction of Administered Dose of [^14C]-Alisertib Excreted in Feces
Time frame: Predose and multiple timepoints post-dose (up to 240 hours)
Ae: Amount of [^14C]-Alisertib Excreted in Urine
Time frame: Predose and multiple timepoints post-dose (up to 240 hours)
Ae: Amount of [^14C]-Alisertib Excreted in Feces
Time frame: Predose and multiple timepoints post-dose (up to 240 hours)
Percent of Total Radioactivity (TRA) in Urine and Feces
Time frame: Predose and multiple timepoints post-dose (up to 240 hours)
Fe: Fraction of Administered Dose of Alisertib Excreted in Urine
Time frame: Predose and multiple timepoints post-dose (up to 240 hours)
Ae: Amount of Alisertib Excretion in Urine
Time frame: Predose and multiple timepoints post-dose (up to 240 hours)
Renal Clearance (CLR) of Alisertib
Time frame: Predose and multiple timepoints post-dose (up to 240 hours)
Percentage of Alisertib Metabolites in Plasma Following a Single Dose of [^14C]-Alisertib Oral Solution
Total radioactive peak distributions of metabolites in 0 to 192 hours pooled plasma samples from participants.
Time frame: Predose and multiple timepoints post-dose (0 to 192 hours)
Percentage of Alisertib Metabolites in Urine Following a Single Dose of [^14C]-Alisertib Oral Solution
Total radioactive peak distributions of metabolites in 0 to 192 hours pooled urine samples from participants.
Time frame: Predose and multiple timepoints post-dose (0 to 192 hours)
Percentage of Alisertib Metabolites in Feces Following a Single Dose of [^14C]-Alisertib Oral Solution
Total radioactive peak distributions of metabolites in 0 to 192 hours pooled fecal samples from participants.
Time frame: Predose and multiple timepoints post-dose (0 to 192 hours)
Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events
An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) was defined as any AE at any dose that: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in a persistent or significant disability/incapacity or resulted in congenital anomaly/birth defect. A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: From first dose of study drug through 30 days after the last dose of study drug (Up to 117 days)
Number of Participants With Clinically Significant Changes or Abnormalities in Clinical Laboratory Values Reported as AEs
An abnormal laboratory was assessed to be an AE if the value lead to discontinuation or delay in treatment, dose modification, therapeutic intervention, or was considered by the investigator to be a clinically significant change from Baseline.
Time frame: Part A: Day 1 and End of Study (EOS) Day 31 if not continuing to Part B, Part B: Days 8 and 15 of each cycle and EOS (Up to 117 days)
Number of Participants With Clinically Significant Changes or Abnormalities in Vital Sign Measurements
Vital signs included body temperature, heart rate, and sitting blood pressure. The investigator determined if the changes were clinically significant.
Time frame: Part A: Day 1 and EOS (Day 31 if not continuing to Part B), Part B: Day 1 of each cycle and EOS (Up to 117 days)
Participants took part in the study at 1 investigative site in the United States from 24 January 2013 to 14 June 2013.
| Milestone | Alisertib |
|---|---|
| Started | 3 |
| Completed | 3 |
| Not completed | 0 |
| Milestone | Alisertib |
|---|---|
| Started | 3 |
| Completed | 0 |
| Not completed | 3 |
| Withdrew: Progressive disease | 3 |
| nanomole (nmol)/liter (L) | Alisertib |
|---|---|
| Alisertib | 2183.3 ± 161.97 |
| Drug-Related Material | 2606.7 ± 228.98 |
| hr | Alisertib |
|---|---|
| Alisertib | 1.00 ± 161.97 |
| Drug-Related Material | 1.00 ± 228.98 |
| hour (hr)*nmol/L | Alisertib |
|---|---|
| Alisertib | 16800.0 ± 4936.60 |
| Drug-Related Material | 37033.3 ± 20545.15 |
| hr*nmol/L | Alisertib |
|---|---|
| Alisertib | 17266.7 ± 5138.42 |
| Drug-Related Material | 42233.3 ± 23302.43 |
| hour | Alisertib |
|---|---|
| Alisertib | 23.40 ± 7.041 |
| Drug-Related Material | 42.03 ± 25.255 |
| L/hr | Alisertib |
|---|---|
| CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Plasma Concentration for Alisertib Following a Single Dose of [^14C]-Alisertib Oral Solution | 4.06 ± 25.6 |
| ratio | Alisertib |
|---|---|
| Ratio of Whole Blood Total Radioactivity (TRA) Cmax to Plasma TRA Cmax | 0.6550 ± 0.0671 |
| ratio | Alisertib |
|---|---|
| Ratio of Alisertib Plasma Cmax to Drug-Related Material TRA Plasma Cmax | 0.8397 ± 0.0589 |
| ratio | Alisertib |
|---|---|
| Ratio of Whole Blood TRA AUClast to Plasma TRA AUClast | 0.5950 ± 0.1010 |
| ratio | Alisertib |
|---|---|
| Ratio of Alisertib Plasma AUClast to Drug-Related Material TRA Plasma AUClast | 0.4997 ± 0.1364 |
| ratio | Alisertib |
|---|---|
| Ratio of Whole Blood TRA AUC∞ to Plasma TRA AUC∞ | 0.6750 ± 0.0170 |
| ratio | Alisertib |
|---|---|
| Ratio of Alisertib Plasma AUC∞ to Drug-Related Material TRA Plasma AUC∞ | 0.4490 ± 0.1204 |
| percent of dose | Alisertib |
|---|---|
| Fe: Fraction of Administered Dose of [^14C]-Alisertib Excreted in Urine | 2.650 ± 1.7935 |
| percent of dose | Alisertib |
|---|---|
| Fe: Fraction of Administered Dose of [^14C]-Alisertib Excreted in Feces | 87.833 ± 2.2898 |
| nanogram equivalent [ng(eq)] | Alisertib |
|---|---|
| Ae: Amount of [^14C]-Alisertib Excreted in Urine | 939420.7 ± 632770.92 |
| ng(eq) | Alisertib |
|---|---|
| Ae: Amount of [^14C]-Alisertib Excreted in Feces | 31156703.0 ± 764243.97 |
| percent of TRA | Alisertib |
|---|---|
| Percent of Total Radioactivity (TRA) in Urine and Feces | 90.500 ± 1.3115 |
| percent of dose | Alisertib |
|---|---|
| Fe: Fraction of Administered Dose of Alisertib Excreted in Urine | 0.009045 ± 0.000714 |
| ng | Alisertib |
|---|---|
| Ae: Amount of Alisertib Excretion in Urine | 3215.0 ± 219.20 |
| L/hr | Alisertib |
|---|---|
| Renal Clearance (CLR) of Alisertib | 0.000687 ± 0.000013 |
Total radioactive peak distributions of metabolites in 0 to 192 hours pooled plasma samples from participants.
| percent of plasma AUC0-192hr | Alisertib |
|---|---|
| Metabolite M1 | 12.0 |
| Metabolite M2 | 34.6 |
| Metabolite M3 | 5.6 |
Total radioactive peak distributions of metabolites in 0 to 192 hours pooled urine samples from participants.
| percent of dose | Alisertib |
|---|---|
| Unknown | 0.24 |
| M8a | 0.28 |
| M9 | 0.66 |
| M536 | 0.14 |
| M1 | 0.84 |
| M8 | 0.37 |
| Others | 0.05 |
Total radioactive peak distributions of metabolites in 0 to 192 hours pooled fecal samples from participants.
| percent of dose | Alisertib |
|---|---|
| M536 | 4.45 |
| M520a | 1.19 |
| M3a | 2.22 |
| M550 | 2.96 |
| M537 | 9.17 |
| M520b | 1.72 |
| M3 | 20.82 |
| M520c | 5.94 |
| Alisertib | 26.27 |
| M2 | 8.62 |
| Others | 0 |
An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) was defined as any AE at any dose that: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in a persistent or significant disability/incapacity or resulted in congenital anomaly/birth defect. A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving study drug.
| Participants | Alisertib |
|---|---|
| Any AE | 3 |
| SAE | 0 |
An abnormal laboratory was assessed to be an AE if the value lead to discontinuation or delay in treatment, dose modification, therapeutic intervention, or was considered by the investigator to be a clinically significant change from Baseline.
| Participants | Alisertib |
|---|---|
| Neutrophil Count Decreased | 1 |
| Neutropenia | 1 |
| Blood Magnesium Decreased | 1 |
Vital signs included body temperature, heart rate, and sitting blood pressure. The investigator determined if the changes were clinically significant.
| Participants | Alisertib |
|---|---|
| Number of Participants With Clinically Significant Changes or Abnormalities in Vital Sign Measurements | 0 |
Collected over From first dose of study drug through 30 days after the last dose of study drug (Up to 117 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alisertib | — | 0/3 (0%) | 3/3 (100%) |
| Event | Alisertib |
|---|---|
| FatigueGeneral disorders | 2/3 |
| AlopeciaSkin and subcutaneous tissue disorders | 2/3 |
| NauseaGastrointestinal disorders | 1/3 |
| VomitingGastrointestinal disorders | 1/3 |
| GlossodyniaGastrointestinal disorders | 1/3 |
| PyrexiaGeneral disorders | 1/3 |
| ChillsGeneral disorders | 1/3 |
| Oedema peripheralGeneral disorders | 1/3 |
| Back painMusculoskeletal and connective tissue disorders | 1/3 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 1/3 |
Safety Population included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Alisertib |
|---|---|
| Mean | 64.0 ± 13.11 |
| Sex: Female, Male(Participants) | Alisertib |
|---|---|
| Female | 1 |
| Male | 2 |
| Race/Ethnicity, Customized(participants) | Alisertib |
|---|---|
| Not Hispanic or Latino | 3 |
| Race/Ethnicity, Customized(participants) | Alisertib |
|---|---|
| White | 2 |
| Black or African American | 1 |
| Region of Enrollment(participants) | Alisertib |
|---|---|
| United States | 3 |
| Height(cm) | Alisertib |
|---|---|
| Mean | 173.5 ± 7.15 |
| Weight(kg) | Alisertib |
|---|---|
| Mean | 80.27 ± 20.760 |
| Body Mass Index (BMI)(kg/m^2) | Alisertib |
|---|---|
| Mean | 26.91 ± 8.346 |
Ran from Jan 2013 to primary completion in Apr 2013, 2 months.
Results were first posted in Oct 2018, 5 years 6 months after primary completion.
Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 2 months is below that.
Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MLN 8237
Millennium Pharmaceuticals, Inc. →